Phase II Single-Arm Study of Preoperative Letrozole for Estrogen Receptor-Positive Postmenopausal Ductal Carcinoma In Situ: CALGB 40903 (Alliance).

E. Shelley Hwang,Terry Hyslop,Laura H. Hendrix,Stephanie Duong,Isabelle Bedrosian,Elissa R. Price,Abigail S. Caudle,Tina J. Hieken,J. M. Guenther,Clifford A. Hudis,Eric P. Winer,Alan P. Lyss,Diana Dickson-Witmer,Richard A. Hoefer,David W. Ollila,Timothy Hardman,Jeffrey R. Marks,Yunn-Yi Chen,Gregor Krings,Laura J. Esserman,Nola M. Hylton

Phase II Single-Arm Study of Preoperative Letrozole for Estrogen Receptor-Positive Postmenopausal Ductal Carcinoma In Situ: CALGB 40903 (Alliance).

2020

PURPOSEPrimary endocrine therapy for ductal carcinoma in situ (DCIS) as a potential alternative to surgery has been understudied. This trial explored the feasibility of a short-term course of letro...

Keywords:

Estrogen receptor
Endocrine system
Ductal carcinoma
Oncology
Letrozole
Pathology
Single Arm Study
Internal medicine
In situ
Medicine
endocrine therapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations